Sanjay Ahuja

Sanjay Ahuja

Auto-generated profile, based on publicly available information

Sanjay Ahuja

Rainbow Hemostasis & Thrombosis Center, University Hospitals Rainbow Babies and Children's Hospital Case Western Reserve University School of Medicine Cleveland Ohio USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2022 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
YAYazan Abou-Ismail
Yazan Abou-Ismail
SKSargam Kapoor
Sargam Kapoor
DSDivyaswathi Citla Sridhar
Divyaswathi Citla Sridhar
LNLalitha Nayak
Lalitha Nayak
SASanjay Ahuja
Sanjay Ahuja
The thrombotic microangiopathies (TMAs) are a heterogenous group of disorders with distinct pathophysiologies that cause occlusive microvascular or macrovascular thrombosis, and are characterized by microangiopathic hemolytic anemia, thrombocytopenia, and/or end‐organ ischemia. TMAs are associated with significant morbidity and mortality, and data on the management of certain TMAs are often lacking. The nomenclature, classification, and management of various TMAs is constantly evolving as we learn more about these rare syndromes. Thorough clinical and laboratory evaluation is essential to distinguish various TMAs and arrive at an accurate diagnosis, which is key for appropriate management. In this illustrated review, we focus on thrombotic thrombocytopenic purpura (TTP), Shiga toxin–associated hemolytic uremic syndrome, complement‐mediated hemolytic uremic syndrome, hematopoietic cell transplant‐associated TMA, and drug‐induced TMA, and describe their incidence, pathophysiology, diagnosis, and management. We also highlight emerging complement‐directed therapies under investigation for the management of complement‐mediated TMAs.

26 April 2022 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
SPSina Pourang
Sina Pourang
USUjjal D.S. Sekhon
Ujjal D.S. Sekhon
DDDante Disharoon
Dante Disharoon
SASanjay P. Ahuja
Sanjay P. Ahuja
MSMichael A. Suster
Michael A. Suster
PMPedram Mohseni
Pedram Mohseni

7 July 2019 in Haemophilia
Verified
Journal Article
Closed access
PDF file
DMDebnath Maji
Debnath Maji
LNLalitha Nayak
Lalitha Nayak
JMJanet Martin
Janet Martin
USUjjal D. S. Sekhon
Ujjal D. S. Sekhon
AGAnirban Sen Gupta
Anirban Sen Gupta
SASanjay P. Ahuja
Sanjay P. Ahuja

3 July 2023 in IEEE Transactions on Biomedical Circuits and Systems
Verified
Journal Article
Closed access
CDChristopher A. Delianides
Christopher A. Delianides
SPSina Pourang
Sina Pourang
SHSelvin Hernandez
Selvin Hernandez
DDDante Disharoon
Dante Disharoon
SASanjay P. Ahuja
Sanjay P. Ahuja
MSMichael A. Suster
Michael A. Suster
This paper presents a standalone, multichannel, miniaturized impedance analyzer (MIA) system for dielectric blood coagulometry measurements with a microfluidic sensor termed ClotChip. The system incorporates a front-end interface board for 4-channel impedance measurements at an excitation frequency of 1 MHz, an integrated resistive heater formed by a pair of printed-circuit board (PCB) traces to keep the blood sample near a physiologic temperature of 37°C, a software-defined instrument module for signal generation and data acquisition, and a Raspberry Pi-based embedded computer with 7-inch touchscreen display for signal processing and user interface. When measuring fixed test impedances across all four channels, the MIA system exhibits an excellent agreement with a benchtop impedance analyzer, with rms errors of ≤0.30% over a capacitance range of 47–330 pF and ≤0.35% over a conductance range of 2.13–10 mS. Using in vitro -modified human whole blood samples, the two ClotChip output parameters, namely, the time to reach a permittivity peak ( Tpeak ) and maximum change in permittivity after the peak (Δϵ r,max ) are assessed by the MIA system and benchmarked against the corresponding parameters of a rotational thromboelastometry (ROTEM) assay. Tpeak exhibits a very strong positive correlation (r = 0.98, p < 10 -6 , n = 20) with the ROTEM clotting time ( CT ) parameter, while Δϵ r,max exhibits a very strong positive correlation (r = 0.92, p < 10 -6 , n = 20) with the ROTEM maximum clot firmness ( MCF ) parameter. This work shows the potential of the MIA system as a standalone, multichannel, portable platform for comprehensive assessment of hemostasis at the point-of-care/point-of-injury (POC/POI).

12 June 2018 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
PDF file
JMJohnny Ndoni Mahlangu
Johnny Ndoni Mahlangu
SASanjay P. Ahuja
Sanjay P. Ahuja
JWJerzy Windyga
Jerzy Windyga
NCNikki Church
Nikki Church
ASAnita Shah
Anita Shah
LSLawrence Schwartz
Lawrence Schwartz
BAY 81-8973 (Kovaltry®) is an unmodified, full-length recombinant factor VIII (rFVIII) approved for the prevention and treatment of bleeding episodes in patients with hemophilia A. The amino acid sequence for BAY 81-8973 is identical to that of sucrose-formulated rFVIII (rFVIII-FS; Kogenate® FS/KOGENATE®, Bayer), but the two products differ in their manufacturing approaches. The manufacture of BAY 81-8973 includes several modifications and enhancements, such as the introduction of the gene for human heat shock protein 70, a molecular chaperone protein that facilitates folding of proteins; no addition of human- or animal-derived proteins in the cell culture, purification process, or final formulation; and use of a 20-nm filter to remove any potential aggregates and pathogens. BAY 81-8973 was extensively studied in the LEOPOLD clinical development program, which enrolled participants of all age groups (children, adolescents, and adults) with severe hemophilia A. The pharmacokinetic profile of BAY 81-8973 was shown to be noninferior to, and for some variables more favorable than, rFVIII-FS and another commercial full-length rFVIII product. BAY 81-8973 was shown to be efficacious when used for prophylaxis, on-demand treatment, and perioperative hemostasis. The efficacious prophylaxis dose of BAY 81-8973 was approximately 20–40 IU/kg given two or three times per week, which achieved low annualized bleeding rates. Either the one-stage or the chromogenic assay provides accurate measurements for postinfusion monitoring of BAY 81-8973 levels, with no product-specific calibration standard needed. The incidence of treatment-related adverse events was ⩽7% across all LEOPOLD studies, and no previously treated patient developed anti-BAY 81-8973 inhibitors in the completed primary studies.

5 November 2020 in Blood
Verified
Journal Article
Open access
SASanjay Ahuja
Sanjay Ahuja
KFKathelijn Fischer
Kathelijn Fischer
TBTina Biss
Tina Biss
MEMonika Maas Enriquez
Monika Maas Enriquez
MMMaria-Elisa Mancuso
Maria-Elisa Mancuso
Gili KenetGili Kenet
Gili Kenet
IntroductionBAY 94-9027 (damoctocog alfa pegol) is an extended-half-life PEGylated recombinant factor VIII approved for use in patients with hemophilia A aged ≥